Trial Profile
Phase II study of ramucirumab plus paclitaxel therapy for elderly patients with non-resectable or metastatic gastric cancer (T-CORE1501)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Apr 2017
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Ramucirumab (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- 13 May 2016 New trial record